spironolactone has been researched along with Apnea, Obstructive Sleep in 15 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aldosterone excretion was determined by 24 h urine (24h-UAldo) collected at randomization and after 6 months of follow-up." | 6.84 | Effects of continuous positive airway pressure treatment on aldosterone excretion in patients with obstructive sleep apnoea and resistant hypertension: a randomized controlled trial. ( Cavalcanti, AH; Cortez, AF; de Souza, F; Margallo, V; Muxfeldt, ES; Salles, GF, 2017) |
| "INTRODUCTION Obstructive sleep apnea (OSA) is considered to be one of the major causes of resistant arterial hypertension (RAH)." | 6.82 | Effect of eplerenone on the severity of obstructive sleep apnea and arterial stiffness in patients with resistant arterial hypertension. ( Cofta, S; Krasińska, B; Krasiński, Z; Miazga, A; Pawlaczyk-Gabriel, K; Szczepaniak-Chicheł, L; Trafas, T; Tykarski, A, 2016) |
| "A close association exists between hyperaldosteronism, RHTN, and obstructive sleep apnea (OSA) based upon recent studies which indicate that OSA is worsened by aldosterone-mediated fluid retention." | 6.48 | Resistant hypertension and aldosterone: an update. ( Ahmed, MI; Calhoun, DA; Clark, D, 2012) |
| "Features of visceral obesity and obstructive sleep apnea that may stimulate aldosterone secretion are described here." | 6.44 | Obesity, sleep apnea, aldosterone, and hypertension. ( Goodfriend, TL, 2008) |
| "Fifteen patients with severe OSA, hypertension, and diastolic heart failure were hospitalized to receive IV furosemide, 20 mg, and spironolactone, 100 mg, bid for 3 days." | 3.74 | Diuretics in obstructive sleep apnea with diastolic heart failure. ( Battisti, A; Brussino, L; Bucca, CB; Cicolin, A; Mangiardi, L; Mutani, R; Rolla, G, 2007) |
| "Aldosterone excretion was determined by 24 h urine (24h-UAldo) collected at randomization and after 6 months of follow-up." | 2.84 | Effects of continuous positive airway pressure treatment on aldosterone excretion in patients with obstructive sleep apnoea and resistant hypertension: a randomized controlled trial. ( Cavalcanti, AH; Cortez, AF; de Souza, F; Margallo, V; Muxfeldt, ES; Salles, GF, 2017) |
| "INTRODUCTION Obstructive sleep apnea (OSA) is considered to be one of the major causes of resistant arterial hypertension (RAH)." | 2.82 | Effect of eplerenone on the severity of obstructive sleep apnea and arterial stiffness in patients with resistant arterial hypertension. ( Cofta, S; Krasińska, B; Krasiński, Z; Miazga, A; Pawlaczyk-Gabriel, K; Szczepaniak-Chicheł, L; Trafas, T; Tykarski, A, 2016) |
| "Patients are diagnosed as having resistant hypertension when they have blood pressure readings that remain above goal despite the concomitant use of 3 optimally dosed antihypertensive agents from different classes, with 1 of the agents being a diuretic." | 2.48 | Evaluation and pharmacologic approach to patients with resistant hypertension. ( Adams, M; Bellone, JM; Rutecki, GW; Wright, BM, 2012) |
| "A close association exists between hyperaldosteronism, RHTN, and obstructive sleep apnea (OSA) based upon recent studies which indicate that OSA is worsened by aldosterone-mediated fluid retention." | 2.48 | Resistant hypertension and aldosterone: an update. ( Ahmed, MI; Calhoun, DA; Clark, D, 2012) |
| "Features of visceral obesity and obstructive sleep apnea that may stimulate aldosterone secretion are described here." | 2.44 | Obesity, sleep apnea, aldosterone, and hypertension. ( Goodfriend, TL, 2008) |
| "Refractory hypertension (RfHT) and obstructive sleep apnea (OSA) share common pathophysiological mechanisms and probably are intrinsically associated, but their prevalence, clinical profile, and polysomnography (PSG) pattern remain misunderstood." | 1.72 | Prevalence and associated factors of obstructive sleep apnea in refractory hypertension. ( Cavalcanti, AH; Chedier, B; de Souza, F; Muxfeldt, ES; Roderjan, CN, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chedier, B | 1 |
| Roderjan, CN | 1 |
| Cavalcanti, AH | 2 |
| de Souza, F | 2 |
| Muxfeldt, ES | 2 |
| Tang, ZP | 1 |
| Wu, ZM | 1 |
| Li, WB | 1 |
| Wu, YJ | 1 |
| Zheng, T | 1 |
| Kasai, T | 1 |
| Bradley, TD | 2 |
| Friedman, O | 1 |
| Logan, AG | 1 |
| Krasińska, B | 1 |
| Miazga, A | 1 |
| Cofta, S | 1 |
| Szczepaniak-Chicheł, L | 1 |
| Trafas, T | 1 |
| Krasiński, Z | 1 |
| Pawlaczyk-Gabriel, K | 1 |
| Tykarski, A | 1 |
| Margallo, V | 1 |
| Cortez, AF | 1 |
| Salles, GF | 1 |
| Morton, A | 1 |
| Laurie, J | 1 |
| Goodfriend, TL | 1 |
| Yumino, D | 1 |
| Wang, H | 1 |
| Floras, JS | 1 |
| Newton, GE | 1 |
| Mak, S | 1 |
| Ruttanaumpawan, P | 1 |
| Parker, JD | 1 |
| Gaddam, K | 1 |
| Pimenta, E | 2 |
| Thomas, SJ | 1 |
| Cofield, SS | 1 |
| Oparil, S | 2 |
| Harding, SM | 1 |
| Calhoun, DA | 3 |
| Egan, BM | 1 |
| Adams, M | 1 |
| Bellone, JM | 1 |
| Wright, BM | 1 |
| Rutecki, GW | 1 |
| Clark, D | 1 |
| Ahmed, MI | 1 |
| Alam, S | 1 |
| Palevsky, HI | 1 |
| Bucca, CB | 1 |
| Brussino, L | 1 |
| Battisti, A | 1 |
| Mutani, R | 1 |
| Rolla, G | 1 |
| Mangiardi, L | 1 |
| Cicolin, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Continuous Positive Airway Pressure (CPAP) on Blood Pressure Control of Resistant Hypertension Patients With Obstructive Sleep Apnea Syndrome (OSAS).[NCT01508754] | Phase 4 | 125 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| Impact of 3-week SPA Therapy on Sleep Apnea in Patients With Obstructive Sleep Apnea Syndrome and Chronic Venous Insufficiency: A Randomized, Controlled Study[NCT02559427] | 0 participants (Actual) | Interventional | 2016-10-31 | Withdrawn (stopped due to no patients randomized after more than one year sponsor decided to withdrawn the study.) | |||
| Effects of Eplerenone on Left Ventricular Hypertrophy in Patients With Resistant Hypertension and Obstructive Sleep Apnoea[NCT03186742] | Phase 4 | 125 participants (Actual) | Interventional | 2014-07-01 | Completed | ||
| Randomized Controlled Trial of Spironolactone Versus Standard of Care Blood Pressure Treatment on the Severity of Obstructive Sleep Apnea in Patients With Resistant Hypertension[NCT01897727] | 41 participants (Actual) | Interventional | 2009-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 month change in apnea-hypopnea index assessed by diagnostic, full-night polysomnography. AHI values are typically categorized as 5-15/hr = mild; 15-30/hr = moderate; and > 30/h = severe. (NCT01897727)
Timeframe: baseline and 3 months
| Intervention | events/hour (Mean) |
|---|---|
| Spironolactone | -18.3 |
| Standard of Care BP Treatment | 7.0 |
5 reviews available for spironolactone and Apnea, Obstructive Sleep
| Article | Year |
|---|---|
Obesity, sleep apnea, aldosterone, and hypertension.
Topics: Aldosterone; Humans; Hypertension; Metabolic Syndrome; Mineralocorticoid Receptor Antagonists; Obesi | 2008 |
Evaluation and pharmacologic approach to patients with resistant hypertension.
Topics: Antihypertensive Agents; Diuretics; Drug Resistance; Drug Therapy, Combination; Humans; Hypertension | 2012 |
Resistant hypertension and aldosterone: an update.
Topics: Aldosterone; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Humans; Hyperaldosteronis | 2012 |
Standard therapies for pulmonary arterial hypertension.
Topics: Anticoagulants; Calcium Channel Blockers; Comorbidity; Diuretics; Heart Failure; Humans; Hypertensio | 2007 |
Mechanisms and treatment of resistant hypertension.
Topics: Blood Pressure Monitoring, Ambulatory; Contraceptives, Oral; Diuretics; Drug Resistance; Humans; Hyp | 2007 |
4 trials available for spironolactone and Apnea, Obstructive Sleep
| Article | Year |
|---|---|
[Effectiveness of spirolactone on the treatment of laryngeal edema and complications after H-uvulopalatopharyngoplasty for patients with obstructive sleep apnea].
Topics: Humans; Laryngeal Edema; Palate, Soft; Pharynx; Sleep Apnea, Obstructive; Spironolactone; Uvula | 2020 |
Effect of eplerenone on the severity of obstructive sleep apnea and arterial stiffness in patients with resistant arterial hypertension.
Topics: Aged; Eplerenone; Female; Humans; Hypertension; Male; Middle Aged; Severity of Illness Index; Sleep | 2016 |
Effects of continuous positive airway pressure treatment on aldosterone excretion in patients with obstructive sleep apnoea and resistant hypertension: a randomized controlled trial.
Topics: Aged; Aldosterone; Continuous Positive Airway Pressure; Coronary Vasospasm; Diuretics; Female; Follo | 2017 |
Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report.
Topics: Blood Pressure; Diuretics; Drug Resistance; Female; Follow-Up Studies; Humans; Hypertension; Male; M | 2010 |
Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report.
Topics: Blood Pressure; Diuretics; Drug Resistance; Female; Follow-Up Studies; Humans; Hypertension; Male; M | 2010 |
Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report.
Topics: Blood Pressure; Diuretics; Drug Resistance; Female; Follow-Up Studies; Humans; Hypertension; Male; M | 2010 |
Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report.
Topics: Blood Pressure; Diuretics; Drug Resistance; Female; Follow-Up Studies; Humans; Hypertension; Male; M | 2010 |
6 other studies available for spironolactone and Apnea, Obstructive Sleep
| Article | Year |
|---|---|
Prevalence and associated factors of obstructive sleep apnea in refractory hypertension.
Topics: Aged; Blood Pressure Monitoring, Ambulatory; Cross-Sectional Studies; Female; Humans; Hypertension; | 2022 |
Effect of intensified diuretic therapy on overnight rostral fluid shift and obstructive sleep apnoea in patients with uncontrolled hypertension.
Topics: Aged; Blood Pressure; Diuretics; Drug Resistance; Drug Therapy, Combination; Extracellular Fluid; Fe | 2014 |
Eplerenone in the management of resistant hypertension with obstructive sleep apnoea in pregnancy.
Topics: Adult; Eplerenone; Female; Humans; Mineralocorticoid Receptor Antagonists; Obesity, Morbid; Pre-Ecla | 2017 |
Prevalence and physiological predictors of sleep apnea in patients with heart failure and systolic dysfunction.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aged, 80 and over; Body Mass Inde | 2009 |
Overnight rostral fluid shift and obstructive sleep apnea in treatment resistant hypertension: connecting the dots clarifies the picture.
Topics: Aldosterone; Blood Volume; Drug Resistance; Fluid Shifts; Humans; Hypertension; Insulin Resistance; | 2010 |
Diuretics in obstructive sleep apnea with diastolic heart failure.
Topics: Adult; Aged; Blood Gas Analysis; Diastole; Diuretics; Drug Therapy, Combination; Echocardiography, D | 2007 |